Ravikanth Veluri is currently the Sr. Director of ADME at Eli Lilly and Company, a position they have held since 2022. Prior to this role, Ravikanth served as the Director of Biotransformation and Large Molecules at IQVIA/Q2 Solutions from 2019 to 2022. Their extensive experience in the pharmaceutical industry includes positions at Perrigo Company plc as a Global Scientific Affairs Project Manager, Vertex Pharmaceuticals as a Research Scientist II/Sr. Scientist, and Hetero Drugs Ltd as Head of DMPK. Ravikanth completed postdoctoral work at the University of Colorado Health Sciences Center and Colorado State University between 2003 and 2006.
This person is not in the org chart
This person is not in any teams
This person is not in any offices